India's Medicamen Biotech gains on US FDA nod for blood cancer drug

Medicamen Biotech

03/06/2025 10:40

** Shares of Medicamen Biotech MEBI.NS rise 4% to 434.95  rupees

** Drugmaker gets U.S. FDA approval for Bortezomib injection 3.5 mg

** Bortezomib therapeutically equivalent to Takeda's 4502.T blood cancer drug Velcade

** More than 49,576 shares traded, 2.1x 30-day moving avg

** Stock trims YTD losses to ~3%

 (Reporting by Rudra Pratap Singh in Bengaluru)

 ((rudrapratap.singh@thomsonreuters.com))